Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03847844Phase 1Completed

UCMSCs as Front-line Approach of Treatment for Patients With aGVHD

Role: lead

NCT06129175Phase 2Recruiting

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

Role: lead

NCT05016011Phase 2Completed

Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury

Role: lead

NCT01720888Phase 2Unknown

Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy

Role: collaborator

NCT01456819Phase 2Unknown

Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia

Role: collaborator

NCT01461720Phase 2Unknown

Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct

Role: collaborator

All 6 trials loaded